The Effect of Pre-exercise Feeding on Bone Turnover Biomarkers

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age24-32
SponsorSheffield Hallam University

About this trial

Osteoporosis is a major contributor to loss of independence due to bone fractures and resulting hospital treatments lead to significant morbidity. While pharmacological treatments can reduce consequences of osteoporosis, there is a pressing need for non-pharmacological interventions to improve bone health across the life-course and to reduce likelihood of age-related bone disease.

This study will allow us to determine whether synergistic potentiating effects on bone metabolism are observed in humans in relation to the timing of food ingestion and what recommendations can be made to people with respect to food ingestion and exercise to obtain the maximal bone benefits from aerobic exercise. Furthermore, if we can identify interventions that potentiate bone's response to aerobic exercise in younger adults, then such interventions may have the ability to maximise bone mass in younger adults so that with ageing, the additional bone mineral density and improved bone microarchitecture would extend the time before osteoporotic "fracture thresholds" are reached. Therefore, understanding the bone metabolic response to exercise following fasting and feeding in younger adults is important.

Eligibility criteria

Qualifiers

Male (females excluded to remove the interplay between menstrual cycle and bone turnover)

Caucasian ethnicity

Aged 28 ± 4 years

Are physically active (meet the UK guidelines for physical activity of at least 150 minutes moderate intensity activity and/or at least 75 minutes of vigorous intensity activity per week)

Disqualifiers

Current smokers

Excessive alcohol consumption (max 15 alcohol units/week)

Any musculoskeletal injury/disabilities

Any conditions known to affect bone metabolism (e.g. uncontrolled hyper-/hypothyroidism, hyperparathyroidism, hypo-/hypercalcaemia) or malabsorption syndromes (e.g. Crohn's disease, coeliac disease or inflammatory bowel disease).

Trial design

Treatments tested in this trial

  • Breakfast only
  • FAST
  • FED

Treatment groups

16 Participants
are divided into 3 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Sheffield Hallam University

Lead sponsor

Anglia Ruskin University

Collaborator

University of Sheffield

Collaborator

Manchester Metropolitan University

Collaborator

Sheffield Teaching Hospitals NHS Foundation Trust

Collaborator